Vanda Pharmaceuticals Inc. announced the results from its Phase III study of tradipitant in motion sickness, confirming the previously reported results demonstrating that tradipitant is effective in the prevention of vomiting associated with motion sickness
HOPE study demonstrates that local inflammation is a suitable target for treatment in patients with debilitating disease1
The purpose of the study is to test the effect of Sitagliptin on the healing of stable, nonhealing diabetic foot...
A new comparative effectiveness analysis, published online in Wound Repair & Regeneration, reported that Apligraf, from Novartis, has demonstrated improved...
Osteoarthritis (OA) most commonly affects knee joints, and the next most commonly affected sites are the hands and hips.
Topline results were reported from the U.S. Phase III 596 patient HANDEL study of Toctino(alitretinoin) from Basilea Pharma in severe...
GSK informed Basilea that it has elected to discontinue its U.S. alitretinoin (Toctino) program. Global rights to Toctino (alitretinoin) were...
Merz North America has announced that Radiesse has received FDA approval for hand augmentation to correct volume loss in the...
LEO Pharma announced positive results of the DELTA 2 trial. DELTA 2 is the second of two pivotal phase III clinical trials with delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor, for the potential treatment of adults with moderate to severe chronic hand eczema (CHE).
Leo Pharma A/S announces that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for delgocitinib cream, an investigational product and topical pan-Janus kinase (JAK) inhibitor for the treatment of adult patients with moderate to severe chronic hand eczema (CHE)